BIRC5基因rs9904341多态性与乳腺癌易感性的关联研究

任林; 郭美; 魏昆; 魏宏屹; 齐晓伟; 姜军

doi:10.16016/j.1000-5404.201805065

您当前的位置：

首页 >

文章列表页 >

BIRC5基因rs9904341多态性与乳腺癌易感性的关联研究

临床医学 | 更新时间：2026-01-09

- BIRC5基因rs9904341多态性与乳腺癌易感性的关联研究
- Association between BIRC5 rs9904341 polymorphism and breast cancer susceptibility
- 第三军医大学学报 2018年40卷第14期页码：1306-1310
- 作者机构：
  
  1.400038 重庆，陆军军医大学(第三军医大学)第一附属医院：乳腺外科
  2.400038 重庆，陆军军医大学(第三军医大学)第一附属医院：检验科
- 作者简介：
  
  [齐晓伟，E-mail：qxw9908@foxmail.com QI Xiaowei, E-mail: qxw9908@foxmail.com
- 基金信息：
  
  陆军军医大学苗圃人才培养计划(2017MPRC-18);陆军军医大学第一附属医院重大领域技术创新一般项目(SWH2016ZDCX4403)
- DOI：10.16016/j.1000-5404.201805065
  中图分类号： R195.4; R394.5; R737.9
- 收稿：2018-05-09，
  
  修回：2018-06-08，
  
  纸质出版：2018-07-30
- 稿件说明：
移动端阅览
任林, 郭美, 魏昆, 等. BIRC5基因rs9904341多态性与乳腺癌易感性的关联研究[J]. 第三军医大学学报, 2018,40(14):1306-1310.

Lin REN, Mei GUO, Kun WEI, et al. Association between BIRC5 rs9904341 polymorphism and breast cancer susceptibility[J]. Journal of Third Military Medical University, 2018, 40(14): 1306-1310.
任林, 郭美, 魏昆, 等. BIRC5基因rs9904341多态性与乳腺癌易感性的关联研究[J]. 第三军医大学学报, 2018,40(14):1306-1310. DOI： 10.16016/j.1000-5404.201805065.

Lin REN, Mei GUO, Kun WEI, et al. Association between BIRC5 rs9904341 polymorphism and breast cancer susceptibility[J]. Journal of Third Military Medical University, 2018, 40(14): 1306-1310. DOI： 10.16016/j.1000-5404.201805065.

摘要

目的

探索BIRC5基因-31G>C(rs9904341)位点多态性与乳腺癌易感性的关联。

方法

采用病例对照研究设计，纳入新发女性乳腺癌患者709例和749例健康对照，提取研究对象外周血细胞基因组DNA，通过聚合酶链反应-连接酶反应(PCR-LDR)对rs9904341位点进行基因分型，多因素Logistic回归分析-31G>C(rs9904341)位点多态性与乳腺癌易感性的关联。

结果

病例组中GG、GC、CC基因型分布分别为191(26.9%)、354(49.9%)、164(23.1%)；对照组中GG、GC、CC基因型分布分别为184(24.6%)、382(51.0%)、183(24.4%)。基因型频率分布差异无统计学意义(

=0.566)。基于共显性、显性、隐性、等位基因模型，rs9904341位点与乳腺癌易感性均无显著性关联(

0.05)。在

50岁年龄组和已绝经女性人群，显性模型中显性基因者(GC+CC)相比于GG基因型者患乳腺癌的风险显著降低，效应值分别为：校正

=0.61，95%

=0.38~0.96，

=0.031以及校正

=0.63，95%

=0.42~0.95，

=0.029。

结论

BIRC5基因-31G>C(rs9904341)位点多态性与乳腺癌易感性无显著关联，在>50岁年龄组和已绝经女性人群中，C等位基因携带者(CG+CC)较GG基因型者患乳腺癌易感性显著降低。

Abstract

Objective

To investigate the association between BIRC5 -31G>C (rs9904341) polymorphism and breast cancer susceptibility.

Methods

A case-control study was performed on 709 female breast cancer patients freshly-diagnosed by pathology and 749 female healthy control subjects admitted in our hospital from January 2012 to August 2013. Genomic DNA was extracted from their peripheral blood cells

and polymerase chain reaction-ligase detection reaction (PCR-LDR) was used to genotype the polymorphism of rs9904341. Multivariate logistic regression analysis was applied to evaluate the association between -31G>C (rs9904341) polymorphism and breast cancer susceptibility.

Results

The genotype distributions for GG

GC and CC were 191 (26.9%)

354 (49.9%) and 164 (23.1%) respectively for the case group

and 184 (24.6%)

382 (51.0%) and 183 (24.4%) separately in the control group. But there was no significant difference in the genotype distributions between the case and control groups (

=0.566). Under the co-dominant

dominant

recessive models and allele models

no statistically significant differences were found between rs9904341 polymorphism and breast cancer susceptibility (P

0.05). Stratified analyses showed the C allele carriers (CG+CC) had significant lower risk of breast cancer than those with GG and menopause women

with adjusted

=0.61

95%

=0.38~0.96

=0.031 in those over 50 years old

and adjusted

=0.63

95%

=0.42~0.95

=0.029 for the post-menopause women.

Conclusion

No obvious association is found between BIRC5 -31G>C (rs9904341) polymorphism and breast cancer susceptibility. The C allele carriers (CG+CC) have significant lower risk of breast cancer than those with GG in the women older than 50 years and post-menopause.

关键词

Keywords

references

FAN L, STRASSER-WEIPPL K, Li J J, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289. DOI: 10.1016/S1470-2045(13)70567-9.

HOWELL A, ANDERSON A S, CLARKE R B, et al. Risk determination and prevention of breast cancer[J]. Breast Cancer Res, 2014, 16(5): 446. DOI: 10.1186/s13058-014-0446-2.

LI F, AMBROSINI G, CHU E Y, et al. Control of apoptosis and mitotic spindle checkpoint by survivin[J]. Nature, 1998, 396(6711): 580-584. DOI: 10.1038/25141.

ALTIERI D C. The molecular basis and potential role of survivin in cancer diagnosis and therapy[J]. Trends Mol Med, 2001, 7(12): 542-547. DOI: 10.1016/s1471-4914(01)02243-2.

HINNIS A R, LUCKETT J C, WALKER R A. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients[J]. Br J Cancer, 2007, 96(4): 639-645. DOI:10.1038/sj.bjc.6603616.

PETRARCA C R, BRUNETTO A T, DUVAL V, et al. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage Ⅱ and stage Ⅲ breast cancer[J]. Clin Breast Cancer, 2011, 11(2): 129-134. DOI: 10.1016/j.clbc.2011.03.002.

AI Z, YIN L, ZHOU X, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer[J]. Cancer, 2006, 107(4): 746-756. DOI: 10.1002/cncr.22044.

LI F, ALTIERI DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression[J]. Cancer Res, 1999, 59(13): 3143-3151.

OTAKI M, HATANO M, KOBAYASHI K, et al. Cell cycle-dependent regulation of TIAP/m-survivin expression[J]. Biochim Biophys Acta, 2000, 1493(1-2): 188-194. DOI: 10.1016/s0167-4781(00)00142-1.

CHEUNG CH, CHENG L, CHANG KY, et al. Investigations of survivin: the past, present and future[J]. Front Biosci (Landmark Ed), 2011, 16: 952-961. DOI: 10.2741/3728.

XU Y, FANG F, LUDEWIG G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells[J]. DNA Cell Biol, 2004, 23(9): 527-537. DOI: 10.1089/dna.2004.23.527.

WANG X, HUANG L, XU Y, et al. Association between survivin -31G>C promoter polymorphism and cancer risk: a meta-analysis[J]. Eur J Hum Genet, 2012, 20(7): 790-795. DOI: 10.1038/ejhg.2011.276.

SRIVASTAVA K, SRIVASTAVA A, MITTAL B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis[J]. Mol Biol Rep, 2012, 39(2): 1509-1516. DOI: 10.1007/s11033-011-0889-9.

BAYRAM S. Association between RASSF1A Ala133Ser polymorphism and cancer susceptibility: a meta-analysis involving 8, 892 subjects[J]. Asian Pac J Cancer Prev, 2014, 15(8): 3691-3698. DOI: 10.1007/s00432-013-1524-z.

ZHU Y, LI Y, ZHU S, et al. Association of survivin polymorphisms with tumor susceptibility: a meta-analysis[J]. PLoS ONE, 2013, 8(9): e74778. DOI: 10.1371/journal.pone.0074778.

XU L, ZHOU X, XU L, et al. Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies[J]. Tumour Biol, 2014, 35(2): 1661-1669. DOI: 10.1007/s13277-013-1229-6.

[RASOOL I, AFROZE D, WANI KA, et al. pii: S1526-8209: 30631-30636. DOI: 10.1016/j.clbc.2017.11.011 http://dx.doi.org/10.1016/j.clbc.2017.11.011 .

[Broad Institute. Regulatory chromatin states from DNAse and histone ChIP-Seq (Roadmap Epigenomics Consortium, 2015)[DB/OL ] . https://pubs.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs9904341,2018-04-29 https://pubs.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs9904341,2018-04-29

PROKESCH A, LAZAR MA. A hormone sends instant messages to the genome[J]. Cell, 2011, 145(4): 499-501. DOI: 10.1016/j.cell.2011.04.016.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后

下调RRM2B表达增强乳腺癌细胞辐射敏感性

女性乳腺癌患者的身体意象特点及其与知觉压力、自我关怀和内隐态度的关系研究

乳腺癌脑转移患者预后影响因素分析及预测模型的初步构建

LINC00294通过AKT/mTOR/HIF-1a通路促进乳腺癌细胞的增殖、侵袭与迁移